Halozyme Therapeutics (HALO) CEO Torley received 165,522 Performance Stock Units
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Helen Torley (President and CEO at Halozyme Therapeutics Inc., HALO) reported that they received 165,522 Performance Stock Units on Dec 9, 2025.
- Reporting person
- Torley Helen
- Role
- PRESIDENT AND CEO
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 9, 2025 | Grant or award (A) | Performance Stock UnitsOn 165,522 Common Stock1 | +165,522 | - | - | 165,522 direct |
Holdings before and after
- Performance Stock Units: 0 to 165,522 direct
Footnotes from the filing
- 1. Represents the grant of performance-based vesting Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of HALO common stock. The target number of Restricted Stock Units subject to the award is indicated. Up to two hundred percent (200%) of the target Restricted Stock Units could vest if the average closing price of HALO common stock over a period of 20 consecutive trading days during a four-year performance period following the grant of the award equals or exceeds certain price levels specified in the award (with 50% of target number of units vesting at $115 and an additional 50% of the target number of units vesting at each of $130, $145 and $170) and, in each case, only if the Reporting Person remains employed with the Registrant through the end of the performance period (subject to certain exceptions provided in the applicable award agreement).
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Torley report in this HALO Form 4?
Helen Torley (President and CEO at Halozyme Therapeutics Inc., HALO) reported that they received 165,522 Performance Stock Units on Dec 9, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for HALO
Across the 8 sessions after earlier HALO headlines, the stock closed higher 3 times and lower 5 times, with a median move of 1.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | HALO | SPY |
|---|---|---|---|
| Dec 9, 2025 | Jim Lang Elected to Halozyme's Board of Directors | -1.6% | -0.1% |
| Dec 4, 2025 | Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germanyand 1 other headline that session | -2.6% | +0.1% |
| Nov 25, 2025 | Halozyme to Participate in the 8th Annual Evercore Healthcare Conference | -1.6% | +0.9% |
| Nov 18, 2025 | Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery | -0.7% | -0.8% |
| Nov 7, 2025 | FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myelomaand 1 other headline that session | -0.2% | +0.1% |
| Nov 6, 2025 | Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 | +0.1% | -1.1% |
Earlier insider filings at HALO
- Dec 2, 2025Director Connaughton Bernadette sold $59,356 worth of shares (829 units at $71.60), decreasing direct ownership by 2% to 42,123 units (SEC Form 4)
- Dec 2, 2025SEC Form 4 filed by Halozyme Therapeutics Inc.
- Nov 12, 2025PRESIDENT AND CEO Torley Helen sold $4,167,930 worth of shares (60,000 units at $69.47) and exercised 60,000 shares at a strike of $8.11 (SEC Form 4)
- Nov 12, 2025Director Connaughton Bernadette sold $136,960 worth of shares (2,000 units at $68.48), decreasing direct ownership by 4% to 42,952 units (SEC Form 4)
- Oct 6, 2025SEC Form 4 filed by SVP, CHIEF OPERATING OFFICER Caudill Cortney
Quantisnow market dataNASDAQ
HALO
Halozyme Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for HALO
Full HALO profile on Quantisnow Follow HALO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time